中国卒中临床研究中的溶栓治疗：20年的成就与发展方向 Thrombolytic Therapy in Chinese Stroke Clinical Research: Achievements over the Past Two Decades and Future Directions

2002年，《急性脑梗死六小时以内的静脉溶栓治疗》多中心尿激酶RCT结果的发表，标志着中国缺血性卒中溶栓药物研究的开始。此后，中国脑血管病领域工作者学习国际先进经验，遵循国际指南的指导，不断规范和完善我国缺血性卒中的溶栓治疗。20年后的今天，我国已能独立开展创新研发，新型溶栓药物的不断推出、治疗时间窗的不断突破、联合治疗方案的不断创新，使中国的卒中溶栓研究站到了世界舞台中央。本文以亲历者的视角，回顾近20年来中国缺血性卒中临床研究中溶栓治疗的变革历程。 Abstract: In 2002, the results of multicenter RCT of Intravenous Thrombolysis with Urokinase for Acute Cerebral Infarctions were published, marking the beginning of research on thrombolytic drugs for ischemic stroke in China. Subsequently, Chinese researchers in the field of cerebrovascular disease have cautiously learned from international advanced experience, followed the guidance of international guidelines, and continuously standardized and improved thrombolytic therapy for ischemic stroke in China. Today, two decades later, China is capable of independently carrying out innovative research and development. The continuous introduction of new thrombolytic drugs, the continuous breakthroughs in treatment time windows, and the continuous innovation in combination therapy programs have propelled China’s stroke thrombolysis research to the forefront of the global stage. China’s stroke thrombolytic therapy has undergone two decades of rapid development. This article reviews the transformative journey of thrombolytic therapy in Chinese clinical research on ischemic stroke over the past two decades from the perspective of a participant.